Marc Lallemant

Summary

Affiliation: Harvard School of Public Health
Country: USA

Publications

  1. pmc Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavir
    Tim R Cressey
    Program for HIV Prevention and Treatment IRD URI 174, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand
    Ther Drug Monit 33:25-31. 2011
  2. pmc Switching HIV treatment in adults based on CD4 count versus viral load monitoring: a randomized, non-inferiority trial in Thailand
    Gonzague Jourdain
    Unité Mixte Internationale 174, Institut de Recherche pour le Développement IRD Programs for HIV Prevention and Treatment PHPT, Chiang Mai, Thailand
    PLoS Med 10:e1001494. 2013
  3. pmc Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine
    Marc Lallemant
    Institut de Recherche pour le Développement U174, Universite Paris Descartes, Institut National d Etudes Demographiques, Institut de Recherche pour le Developpment, F 75006, Paris, France
    Clin Infect Dis 50:898-908. 2010
  4. ncbi request reprint Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand
    Marc Lallemant
    Epidemiologie Clinique, Sante Maternelle et Infantile et Sida, Institut de Recherche pour le Developpement, Paris
    N Engl J Med 351:217-28. 2004
  5. pmc Association between detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy and virologic failure
    Gonzague Jourdain
    Institut de Recherche pour le Developpement, UMI 174 PHPT, Thailand
    Clin Infect Dis 50:1397-404. 2010
  6. ncbi request reprint Predictors of 5-year mortality in HIV-infected adults starting highly active antiretroviral therapy in Thailand
    Federica Fregonese
    Program for HIV Prevention and Treatment IRD UMI 174, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand
    J Acquir Immune Defic Syndr 60:91-8. 2012
  7. ncbi request reprint Perinatal zidovudine prophylaxis in HIV type-1-infected pregnant women with thalassaemia carriage in Thailand
    Nelly Briand
    Institut National d Etudes Demographiques, Paris, France
    Antivir Ther 14:117-22. 2009
  8. ncbi request reprint Risk factors for in utero or intrapartum mother-to-child transmission of human immunodeficiency virus type 1 in Thailand
    Gonzague Jourdain
    Institut de Recherche pour le Developpement, UMI 174 Epidemiologie Clinique, Sante Maternelle et Infantile et Sida, Paris, France
    J Infect Dis 196:1629-36. 2007
  9. pmc The interrelated transmission of HIV-1 and cytomegalovirus during gestation and delivery in the offspring of HIV-infected mothers
    Woottichai Khamduang
    Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand
    J Acquir Immune Defic Syndr 58:188-92. 2011
  10. pmc Hematological safety of perinatal exposure to zidovudine in uninfected infants born to HIV type 1-infected women in Thailand
    Nelly Briand
    Institut National d Etudes Démographiques INED, Paris, France
    AIDS Res Hum Retroviruses 26:1163-6. 2010

Collaborators

Detail Information

Publications26

  1. pmc Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavir
    Tim R Cressey
    Program for HIV Prevention and Treatment IRD URI 174, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand
    Ther Drug Monit 33:25-31. 2011
    ..The risk of toxic drug concentrations increases rapidly with IDV/r dose of 600/100 mg for patients less than 50 kg and therapeutic drug monitoring of IDV concentrations would help to reduce the risk of IDV-induced nephrotoxicity...
  2. pmc Switching HIV treatment in adults based on CD4 count versus viral load monitoring: a randomized, non-inferiority trial in Thailand
    Gonzague Jourdain
    Unité Mixte Internationale 174, Institut de Recherche pour le Développement IRD Programs for HIV Prevention and Treatment PHPT, Chiang Mai, Thailand
    PLoS Med 10:e1001494. 2013
    ..The purpose of the study was to determine whether a CD4-based monitoring and switching strategy would provide a similar clinical outcome compared to the standard VL-based strategy in Thailand...
  3. pmc Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine
    Marc Lallemant
    Institut de Recherche pour le Développement U174, Universite Paris Descartes, Institut National d Etudes Demographiques, Institut de Recherche pour le Developpment, F 75006, Paris, France
    Clin Infect Dis 50:898-908. 2010
    ..We hypothesized that a 1-month zidovudine-didanosine course initiated at the same time as single-dose nevirapine (sdNVP) would prevent the selection of nevirapine-resistance mutations...
  4. ncbi request reprint Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand
    Marc Lallemant
    Epidemiologie Clinique, Sante Maternelle et Infantile et Sida, Institut de Recherche pour le Developpement, Paris
    N Engl J Med 351:217-28. 2004
    ..We hypothesized that the administration, in addition to zidovudine, of a single dose of oral nevirapine to mothers during labor and to neonates would further reduce transmission of HIV...
  5. pmc Association between detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy and virologic failure
    Gonzague Jourdain
    Institut de Recherche pour le Developpement, UMI 174 PHPT, Thailand
    Clin Infect Dis 50:1397-404. 2010
    ..There is no simple and efficient method to detect such mutations at the initiation of ART...
  6. ncbi request reprint Predictors of 5-year mortality in HIV-infected adults starting highly active antiretroviral therapy in Thailand
    Federica Fregonese
    Program for HIV Prevention and Treatment IRD UMI 174, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand
    J Acquir Immune Defic Syndr 60:91-8. 2012
    ..To estimate the early and long-term mortalities and associated risk factors in adults receiving highly active antiretroviral therapy (HAART) in Thailand...
  7. ncbi request reprint Perinatal zidovudine prophylaxis in HIV type-1-infected pregnant women with thalassaemia carriage in Thailand
    Nelly Briand
    Institut National d Etudes Demographiques, Paris, France
    Antivir Ther 14:117-22. 2009
    ....
  8. ncbi request reprint Risk factors for in utero or intrapartum mother-to-child transmission of human immunodeficiency virus type 1 in Thailand
    Gonzague Jourdain
    Institut de Recherche pour le Developpement, UMI 174 Epidemiologie Clinique, Sante Maternelle et Infantile et Sida, Paris, France
    J Infect Dis 196:1629-36. 2007
    ..The identification of risk factors for in utero and intrapartum transmission of human immunodeficiency virus type 1 (HIV-1) is crucial to the design and understanding of preventive interventions...
  9. pmc The interrelated transmission of HIV-1 and cytomegalovirus during gestation and delivery in the offspring of HIV-infected mothers
    Woottichai Khamduang
    Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand
    J Acquir Immune Defic Syndr 58:188-92. 2011
    ..01), and overall HIV with overall CMV infection (P = 0.001), and prematurity (P = 0.004). Congenital and acquired CMV infections are strong independent correlates of mother-to-child HIV transmission...
  10. pmc Hematological safety of perinatal exposure to zidovudine in uninfected infants born to HIV type 1-infected women in Thailand
    Nelly Briand
    Institut National d Etudes Démographiques INED, Paris, France
    AIDS Res Hum Retroviruses 26:1163-6. 2010
    ..Despite the differences in hemoglobin levels, grade 3 or 4 anemia did not significantly differ by maternal or infant zidovudine duration. The clinical impact appeared modest, but longer exposure may warrant close monitoring...
  11. ncbi request reprint Higher placental anti-inflammatory IL-10 cytokine expression in HIV-1 infected women receiving longer zidovudine prophylaxis associated with nevirapine
    Sakorn Pornprasert
    Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand
    Curr HIV Res 7:211-7. 2009
    ....
  12. pmc Laboratory and clinical predictors of disease progression following initiation of combination therapy in HIV-infected adults in Thailand
    Trinh Duong
    Institut de Recherche pour le Developpement, IRD UMI 174, Paris, France
    PLoS ONE 7:e43375. 2012
    ..Data on determinants of long-term disease progression in HIV-infected patients on antiretroviral therapy (ART) are limited in low and middle-income settings...
  13. pmc Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children
    Tim R Cressey
    Institut de Recherche pour le Developpement, Program for HIV Prevention and Treatment, UR 174, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand
    Clin Infect Dis 46:1601-8. 2008
    ....
  14. ncbi request reprint Growth of human immunodeficiency virus-uninfected children exposed to perinatal zidovudine for the prevention of mother-to-child human immunodeficiency virus transmission
    Nelly Briand
    Institut National d Etudes Demographiques, Paris, France
    Pediatr Infect Dis J 25:325-32. 2006
    ..Although reducing substantially the number of infected children, the potential adverse consequences of these treatments on the health of HIV-uninfected children need to be assessed...
  15. pmc Analysis of residual perinatal transmission of hepatitis B virus (HBV) and of genetic variants in human immunodeficiency virus and HBV co-infected women and their offspring
    Woottichai Khamduang
    Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand INSERM U966, CHRU Tours, Faculte de Medecine, Universite Francois Rabelais, Tours, France Institut de Recherche pour le Développement IRD UMI 174 Programs for HIV Prevention and Treatment PHPT, Chiang Mai, Thailand
    J Clin Virol 58:415-21. 2013
    ..Limited data are available on the residual MTCT of HBV in human immunodeficiency virus (HIV)-HBV co-infected women...
  16. pmc Long-term survival of HIV-infected children receiving antiretroviral therapy in Thailand: a 5-year observational cohort study
    Intira J Collins
    Institut de Recherche pour le Développement IRD U174, Paris, France
    Clin Infect Dis 51:1449-57. 2010
    ..There are scarce data on the long-term survival of human immunodeficiency virus (HIV)-infected children receiving antiretroviral therapy (ART) in lower-middle income countries beyond 2 years of follow-up...
  17. pmc Early HIV-1 diagnosis using in-house real-time PCR amplification on dried blood spots for infants in remote and resource-limited settings
    Nicole Ngo-Giang-Huong
    département Sociétés et Santé, Institut de Recherche pour le Developpement, U174 Program for HIV Prevention and Treatment, Chiang Mai, Thailand
    J Acquir Immune Defic Syndr 49:465-71. 2008
    ..In resource-limited settings, most perinatally HIV-1-infected infants do not receive timely antiretroviral therapy because early HIV-1 diagnosis is not available or affordable...
  18. doi request reprint Association of low CD4 cell count and intrauterine growth retardation in Thailand
    Johann Cailhol
    Institut de Recherche pour le Developpement, Paris, France UMI 174
    J Acquir Immune Defic Syndr 50:409-13. 2009
    ..Some studies have suggested that HIV infection could increase the risk of IUGR. To confirm this hypothesis, we examined the association between HIV-related factors and the risk of IUGR in Thailand...
  19. pmc Long-term hepatitis B virus (HBV) response to lamivudine-containing highly active antiretroviral therapy in HIV-HBV co-infected patients in Thailand
    Woottichai Khamduang
    Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand
    PLoS ONE 7:e42184. 2012
    ....
  20. ncbi request reprint Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability
    Tim R Cressey
    Harvard School of Public Health, Harvard University, Boston, MA, USA
    J Antimicrob Chemother 55:1041-4. 2005
    ..To assess the steady-state pharmacokinetics of two reduced doses of indinavir boosted with ritonavir (indinavir/ritonavir) in HIV-infected Thai patients...
  21. pmc Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy
    Tim R Cressey
    Department of Medical Technology, Chiang Mai University, Thailand
    AIDS 24:2193-200. 2010
    ....
  22. ncbi request reprint Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy
    Gonzague Jourdain
    Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, USA
    N Engl J Med 351:229-40. 2004
    ..Whether there are clinically significant consequences in mothers who are subsequently treated with a nevirapine-containing regimen is unknown...
  23. pmc Early postpartum pharmacokinetics of lopinavir initiated intrapartum in Thai women
    Tim R Cressey
    Harvard School of Public Health, Boston, Massachusetts, USA
    Antimicrob Agents Chemother 53:2189-91. 2009
    ..2 (8.0 to 17.5) microg/ml, and 4.6 (1.7 to 12.5) microg/ml, respectively, at 41 (12 to 74) h after delivery. All of the women attained adequate LPV levels through 30 days postpartum. No serious adverse events were reported...
  24. ncbi request reprint Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update
    Tim R Cressey
    Harvard School of Public Health, Boston, MA, USA
    Infect Genet Evol 7:333-42. 2007
    ....
  25. pmc Human immunodeficiency virus-hepatitis C virus co-infection in pregnant women and perinatal transmission to infants in Thailand
    Nicole Ngo-Giang-Huong
    Institut de recherche pour le developpement IRD, U174 Program for HIV Prevention and Treatment PHPT, Faculty of Associated Medical Sciences, Department of Medical Technology, 110 Inthawaroros Road, Muang, 50200 Chiang Mai, Thailand
    Int J Infect Dis 14:e602-7. 2010
    ....
  26. ncbi request reprint Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1
    Tim R Cressey
    Harvard School of Public Health, Boston, MA, USA
    J Acquir Immune Defic Syndr 38:283-8. 2005
    ..To determine nevirapine (NVP) plasma levels during the postpartum period after a single intrapartum NVP dose for the prevention of mother-to-child transmission...

Research Grants19

  1. Monitoring HAART in HIV-infected parents in Thailand
    Marc Lallemant; Fiscal Year: 2007
    ..A secondary endpoint is the number of drugs exhausted, taking into account cross-resistance mutations and shared toxicities. A pilot pharmacokinetic sub study will evaluate drug levels in the study population. ..
  2. Lopinavir/ritonavir + zidovudine to prevent perinatal HIV in Thailand
    Marc J Lallemant; Fiscal Year: 2010
    ....
  3. NEVIRAPINE+ZIDOVUDINE--PREVENT PERINATAL HIV IN THAILAND
    Marc Lallemant; Fiscal Year: 2000
    ....
  4. Standard zidovudine plus infant nevirapine to prevent perinatal HIV in Thailand
    Marc Lallemant; Fiscal Year: 2009
    ....
  5. Lopinavir/ritonavir + zidovudine to prevent perinatal HIV in Thailand
    Marc Lallemant; Fiscal Year: 2009
    ....
  6. Lopinavir/ritonavir + zidovudine to prevent perinatal HIV in Thailand
    Marc Lallemant; Fiscal Year: 2007
    ....
  7. Standard zidovudine plus infant nevirapine to prevent perinatal HIV in Thailand
    Marc Lallemant; Fiscal Year: 2007
    ....
  8. Standard zidovudine plus infant nevirapine to prevent perinatal HIV in Thailand
    Marc Lallemant; Fiscal Year: 2006
    ....
  9. Program for HIV Prevention and Treatment-Clinical Trial Unit, Thailand
    Marc Lallemant; Fiscal Year: 2007
    ..It will also strengthen the expertise of the health care workers participating in the research in Thailand, and the knowledge produced will improve the care given in all affected areas. ADMINISTRATIVE COMPONENT: ..
  10. Monitoring HAART in HIV-infected parents in Thailand
    Marc Lallemant; Fiscal Year: 2006
    ..A secondary endpoint is the number of drugs exhausted, taking into account cross-resistance mutations and shared toxicities. A pilot pharmacokinetic sub study will evaluate drug levels in the study population. ..
  11. Monitoring HAART in HIV-infected parents in Thailand
    Marc Lallemant; Fiscal Year: 2004
    ..A secondary endpoint is the number of drugs exhausted, taking into account cross-resistance mutations and shared toxicities. A pilot pharmacokinetic sub study will evaluate drug levels in the study population. ..
  12. Monitoring HAART in HIV-infected parents in Thailand
    Marc Lallemant; Fiscal Year: 2003
    ..A secondary endpoint is the number of drugs exhausted, taking into account cross-resistance mutations and shared toxicities. A pilot pharmacokinetic sub study will evaluate drug levels in the study population. ..
  13. NEVIRAPINE+ZIDOVUDINE--PREVENT PERINATAL HIV IN THAILAND
    Marc Lallemant; Fiscal Year: 2002
    ....
  14. NEVIRAPINE+ZIDOVUDINE--PREVENT PERINATAL HIV IN THAILAND
    Marc Lallemant; Fiscal Year: 2001
    ....
  15. Standard zidovudine plus infant nevirapine to prevent perinatal HIV in Thailand
    Marc J Lallemant; Fiscal Year: 2010
    ....